September 13th 2024
The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.
FDA Approves Treatment for Pollen-Induced Allergic Rhinitis in Children, Adolescents
April 20th 2021The FDA has expanded its approval of short ragweed pollen allergen extract (Ragwitek; ALK) to include treatment for children and adolescents, starting at age 5 years, with short ragweed pollen-induced allergic rhinitis.
Read More
NAPNAP Recommends Continued Health Provider Efforts to Eliminate Teen E-Cigarette Use
March 31st 2021Despite significant decreases in 2020, a large number of adolescents less than 18 years of age continue to use e-cigarettes, with considerable adverse health effects, according to a presentation at the 2021 National Association of Pediatric Nurse Practitioners (NAPNAP) conference.
Read More
Drug Receives FDA Approval for Treating Narcolepsy in Pediatric Patients
October 28th 2018Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients aged 7 to 17 years with narcolepsy.
Read More
FDA Approves Dupilumab as Additional Maintenance Therapy in Certain Children with Asthma
October 22nd 2018The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Read More
Epilepsy Treatment Receives FDA Approval for Use in Children
September 29th 2018The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.
Read More